NNE1

From Wikipedia, the free encyclopedia
Jump to: navigation, search
NNE1
NNEI structure.png
Legal status
Legal status
Identifiers
CAS Number 1338925-11-3
PubChem CID 54752945
ChemSpider 26613275
UNII 7FVT9P642K YesY
Chemical and physical data
Systematic (IUPAC) name: N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide
3D model (Jmol) Interactive image
Formula C24H24N2O
Molar mass 356.47 g/mol

NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018.[1] It was invented by Abbott and has a CB1 receptor pEC50 of 8.9 (i.e. EC50 of approximately 1nM) with around 80x selectivity over the related CB2 receptor.[2] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products.[3] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.[4]

See also[edit]

References[edit]